RecruitingPhase 1/2

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

United States408 participantsStarted 2025-01-30

Plain-language summary

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022.
✓. R/R B-NHL after at least 1 prior lines of systemic therapy.
✓. International Prognostic Index (IPI) 2-5.
✓. Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022.
✓. IPI score of 2 to 5.

What they're measuring

Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest

Timeframe: Up to 6 years 4 months

Number of Participants with Dose Limiting Toxicity (DLTs)

Timeframe: Up to 2 months

Trial details

NCT IDNCT06564038

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-02-28

Contact for this trial

AstraZeneca Clinical Study Information Center

1-877-240-9479 information.center@astrazeneca.com

View on ClinicalTrials.gov More Chronic Lymphocytic Leukaemia trials